Applications of Ranolazine Dihydrochloride in Industrial Manufacturing

As an active pharmaceutical ingredient (API) manufacturer with years of experience in the production of Ranolazine Dihydrochloride, we supply to industrial clients engaged in advanced cardiovascular drug development. On this page, we detail practical, real-world applications in the pharmaceutical sector, specifying formulation requirements, compliance standards, production integration, and typical finished product types for each major downstream use.

1. Formulation of Extended-Release Antianginal Tablets

Pharmaceutical companies use our material in the manufacture of extended-release tablet formulations for chronic angina therapy. In this application, formulators achieve precise delivery profiles by optimizing matrix excipients, ensuring sustained plasma concentrations over 12 hours per dose. Ranolazine Dihydrochloride enters directly during wet granulation, following controlled blending and granule sizing, with stringent in-process control for uniform content. Formulators must follow regional pharmacopoeia monographs and stability protocols, while adjusting the active content to match regulatory bioequivalence standards for antianginal medications.

Industry compliance standards

• USP-NF (United States Pharmacopeia–National Formulary) monograph for Ranolazine
• European Pharmacopoeia (Ph. Eur.) requirements for APIs and finished dosage forms
• ICH Q7 GMP for Active Pharmaceutical Ingredients
• FDA Current Good Manufacturing Practices (21 CFR parts 210/211) for solid oral dosage forms

Typical usage ratio

• 375–1000 mg API per tablet (formulation batch: generally 25–40% API to total tablet weight, adjusted per release profile and tablet mass)

Downstream process integration

• Incorporated during wet granulation or direct blending step before tablet compression
• Followed by drying, milling, blending with excipients, tableting, and film coating
• Implement in-process quality control for API content uniformity and dissolution rates

Final product types

• Extended-release tablets (typically 500 mg and 1000 mg strengths)
• Antianginal prescription medications registered for chronic angina pectoris

2. Manufacture of Fixed-Dose Combination (FDC) Cardiovascular Drugs

Several pharmaceutical manufacturers integrate Ranolazine Dihydrochloride into fixed-dose combination therapies, pairing it with other cardiovascular actives such as beta-blockers or calcium channel blockers. During FDC production, accurate proportioning in the blending stage and robust segregation between actives and excipients establish the dual-action therapeutic profile. This requires exceptional process control to match the dissolution and stability requirements for each API, and continual monitoring of cross-contamination and uniformity as dictated by stringent global FDC development guidelines.

Industry compliance standards

• EMA Guideline on clinical development of fixed combination medicinal products
• WHO Technical Report Series, Annex 6: GMP for Pharmaceutical Products
• FDA “Co-Development of Two or More New Investigational Drugs for Use in Combination” Guidance
• Pharmacopeial standards for mixture API uniformity and dissolution testing

Typical usage ratio

• 150–1000 mg per dosage unit, adjusted to harmonize with partner API and total tablet/capsule mass
• Exact ratios set according to synergistic efficacy and bioequivalence testing

Downstream process integration

• Weighted in during multi-API blend phase, often after granulation of individual actives
• Layered granule or pellet manufacturing to prevent interaction before compression or encapsulation
• Ensured compatibility through forced degradation and stability studies

Final product types

• Oral tablets and capsules with two or more cardiovascular actives
• Prescription fixed-dose combination therapies indicated for angina and hypertension

3. Production of Generic Oral Suspension Formulations

Licensed producers formulate Ranolazine Dihydrochloride into oral suspension dosage forms for populations that require alternatives to tablets, such as geriatric and pediatric patients or those with dysphagia. Suspension preparation requires careful pre-milling and controlled dispersion in aqueous vehicles containing flavor and viscosity enhancers. Compliance with microbial purity and rheological stability standards is critical, with concentration adjusted to maintain both uniform dosing and palatability.

Industry compliance standards

• USP <795> Pharmaceutical Compounding—Nonsterile Preparations
• ICH Q6A Specifications for New Drug Substances and Products
• FDA guidance for development and manufacture of oral liquid drugs
• Ph. Eur. guidelines for oral liquid dosage forms

Typical usage ratio

• 5–50 mg/mL concentration in final suspension, depending on patient age group and administration schedule
• Adjusted based on dosing volume and dispensing accuracy

Downstream process integration

• Introduced post-sieving as a fine powder to pre-mixed aqueous vehicle during suspension compounding
• Followed by homogenization and deaeration to ensure even distribution
• Batch QC sampling for assay and microbial count before filling

Final product types

• Oral suspensions for clinical dispensing
• Unit-dose liquid forms for inpatient and outpatient cardiovascular therapy

4. Bulk API Supply for Contract Manufacturing Organizations (CMOs)

Contract manufacturers rely on high-purity Ranolazine Dihydrochloride for secondary processing and re-packaging into various dosage forms tailored to regional market requirements. The bulk API is supplied after validated crystallization and micronization steps, providing tight particle size distribution and ensuring consistent reprocessing into tablets, capsules, or oral liquids. Traceability documentation and change control records accompany each batch to meet the unique audit needs of global CMO clients.

Industry compliance standards

• EDQM Certificate of Suitability (CEP) for European market supply
• DMF (Drug Master File) registration with FDA and/or Health Canada
• GMP certification per PIC/S
• ISO 9001:2015 Quality Management Systems for API manufacturing

Typical usage ratio

• Varies depending on end-dosage form specifications; CMOs typically request 1–50 kg lot sizes for processing into commercial batch scales

Downstream process integration

• Delivers as micronized powder for direct use in tablet blending, capsule filling, or oral suspension compounding
• Undergoes incoming QC for identification, purity, and residual solvents before use in downstream batch records
• Traceable to batch-specific certificates of analysis supporting secondary manufacturing

Final product types

• Commercial finished pharmaceuticals for regulated markets
• Private-label or white-label cardiovascular drugs for global distribution

5. Coating and Film-Forming Systems for Modified-Release Tablets

Some advanced formulations incorporate Ranolazine Dihydrochloride into polymeric coatings to control drug release rate and reduce dose dumping risk under gastrointestinal pH changes. Here, the API disperses in aqueous or organic coatings, often matched with ethyl cellulose or methacrylate copolymers, requiring high-solubility grades for uniformity. Engineers set API load in the coating solution to regulate burst and sustained release phases, maintaining bioavailability across varied patient GI conditions.

Industry compliance standards

• FDA Inactive Ingredient Database for approved excipients
• EMA Quality of Modified-Release Dosage Forms guidelines
• USP <711> Dissolution testing for modified-release products
• GMP Annex 13 for Investigational Medicinal Products (for clinical trial supplies)

Typical usage ratio

• 1–10% API load in the polymer coating solution, adjusted by targeted dissolution profile and regulatory release requirements

Downstream process integration

• Incorporated into coating suspension pre-spray during tablet pan or fluid-bed coating process
• Real-time in-line monitoring for coating thickness and uniformity
• Validated cleaning protocols to avoid cross-contamination between modified-release and immediate-release lines

Final product types

• Film-coated modified-release tablets
• Long-acting oral solid drugs requiring stable extended-release in variable GI environments